Wah Win, Stirling Rob G, Ahern Susannah, Earnest Arul
Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Department of Allergy, Immunology & Respiratory Medicine, Alfred Health, Melbourne, Victoria, Australia.
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2669-2679. doi: 10.1158/1055-9965.EPI-20-0709. Epub 2020 Sep 18.
Guideline-concordant treatment (GCT) of lung cancer has been observed to vary across geographic regions over the years. However, there is little evidence as to what extent this variation is explained by differences in patients' clinical characteristics versus contextual factors, including socioeconomic inequalities.
This study evaluated the independent effects of individual- and area-level risk factors on geographic and temporal variation in receipt of GCT among patients with lung cancer. Receipt of GCT was defined on the basis of the National Comprehensive Cancer Network guidelines. We used Bayesian spatial-temporal multilevel models to combine individual and areal predictors and outcomes while accounting for geographically structured and unstructured correlation and linear and nonlinear trends.
Our study included 4,854 non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cases, reported to the Victorian Lung Cancer Registry between 2011 and 2018. Area-level data comprised socioeconomic disadvantage and remoteness data at the local government area level in Victoria, Australia. Around 60.36% of patients received GCT, and the rates varied across geographic areas over time. This variation was mainly associated with poor performance status, advanced clinical stages, NSCLC types, public hospital insurance, area-level deprivation, and comorbidities.
This study highlights the need to address disparities in receipt of GCT among patients with lung cancer with poor performance status, NSCLC, advanced clinical stage, stage I-III SCLC, stage III NSCLC, public hospital insurance, and comorbidities, and living in socioeconomically disadvantaged areas.
Two-year mortality outcomes significantly improved with GCT. Interventions aimed at reducing these inequalities could help to improve lung cancer outcomes.
多年来,肺癌的指南一致性治疗(GCT)在不同地理区域存在差异。然而,关于这种差异在多大程度上是由患者临床特征的差异而非包括社会经济不平等在内的背景因素所解释,证据很少。
本研究评估了个体和地区层面风险因素对肺癌患者接受GCT的地理和时间差异的独立影响。GCT的接受情况是根据美国国立综合癌症网络指南定义的。我们使用贝叶斯时空多级模型来结合个体和区域预测因素及结果,同时考虑地理结构和非结构相关性以及线性和非线性趋势。
我们的研究纳入了2011年至2018年期间向维多利亚肺癌登记处报告的4854例非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC)病例。地区层面的数据包括澳大利亚维多利亚州地方政府区域层面的社会经济劣势和偏远程度数据。约60.36%的患者接受了GCT,且随着时间推移,该比例在不同地理区域有所不同。这种差异主要与身体状况差、临床分期晚、NSCLC类型、公立医院保险、地区层面的贫困以及合并症有关。
本研究强调需要解决身体状况差、NSCLC、临床分期晚、I - III期SCLC、III期NSCLC、公立医院保险、合并症以及生活在社会经济劣势地区的肺癌患者在接受GCT方面的差异。
GCT显著改善了两年死亡率结果。旨在减少这些不平等的干预措施有助于改善肺癌治疗结果。